Tissue factor: An enzyme cofactor and a true receptor

Thrombosis and Haemostasis

Volumn 86, Issue 1, 2001, Pages 66-74

  Morrissey, J H ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Factor VII; Factor VIIa; TFPI; Thrombotic risk factors; Tissue factor

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; TISSUE FACTOR BLOOD CLOTTING FACTOR 7A INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; XK 1;

BLOOD CLOTTING; CONFERENCE PAPER; DRUG ACTIVITY; DRUG POTENCY; ENZYME ACTIVITY; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN STRUCTURE; RISK FACTOR; SEPSIS; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 0034917278     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616202     Document Type: Conference Paper

References (139)

1. Blood-borne tissue factor: Another view of thrombosis
2. Tissue factor on the loose
3. Determination of plasma tissue factor antigen and its clinical significance
4. Elevated plasma tissue factor antigen level in patients with disseminated intravascular coagulation
5. Role of tissue factor in disseminated intravascular coagulation
6. Urinary tissue factor in glomerulonephritis: A potential marker of glomerular injury?
7. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation
8. Tissue factor accelerates the activation of coagulation factor VII: The role of a bifunctional coagulation cofactor
9. Activation of factor VII bound to tissue factor: A key early step in the tissue factor pathway of blood coagulation
10. Activation and control of factor VII by activated factor X and thrombin: Isolation and characterization of a single chain form of factor VII
11. Activation of bovine factor VII (pro-convertin) by factor XIIa (activated Hageman factor)
12. Activation of human factor VII in plasma and in purified systems: Roles of activated factor IX, kallikrein, and activated factor XII
13. Activation of human factor VII by activated factors IX and X
14. Activation of coagulation factor VII by tissue-type plasminogen activator
15. Initiation of the extrinsic pathway of blood coagulation: Evidence for the tissue factor dependent autoactivation of human coagulation factor VII
16. Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism
17. Measurement of basal levels of factor VIIa in hemophilia A and B patients
18. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade
19. Isolation of cDNA clones coding for human tissue factor: Primary structure of the protein and cDNA
20. Human tissue factor: cDNA sequence and chromosome localization of the gene
21. Purification of human brain tissue factor
22. Purification of recombinant human tissue factor
23. Structural design and molecular evolution of a cytokine receptor superfamily
24. Lipid association, but not the transmembrane domain, is required for tissue factor activity. Substitution of the transmembrane domain with a phosphatidylinositol anchor
25. Crystal structure of the extracellular region of human tissue factor
26. Structure of the extracellular domain of human tissue factor: Location of the factor VIIa binding site
27. The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab5G9 and TF.5G9 complex
28. Hinge bending within the cytokine receptor superfamily revealed by the 2.4 Å crystal structure of the extracellular domain of rabbit tissue factor
29. The crystal structure of the extracellular domain of human tissue factor refined to 1.7 Å resolution
30. Isolation and characterization of bovine factor VII
31. Purification and properties of human coagulation factor VII
32. Quantitation of factor VII in the plasma of normal and warfarin-treated individuals by radioimmuno assay
33. Characterization of a cDNA coding for human factor VII
34. Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation
35. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor
36. 2+ ion binding sites in factor VIIa and in des(1-38) factor VIIa
37. 2+-binding site in the serine protease domain of human factor VIIa and its role in tissue factor binding and development of catalytic activity
38. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant
39. The roles of factor VII's structural domains in tissue factor binding
40. Tissue factor: Molecular recognition and cofactor function
41. The structural basis of function of the TF. VIIa complex in the cellular initiation of coagulation
42. Factor VIIa's first epidermal growth factor-like domain's role in catalytic activity
43. Allosteric regulation of the cofactor dependent serine protease coagulation factor VIIa
44. The location of the active site of blood coagulation factor VIIa above the membrane surface and its reorientation upon association with tissue factor - A fluorescence energy transfer study
45. Tissue factor positions and maintains the factor VIIa active site far above the membrane surface even in the absence of the factor VIIa Gla domain - A fluorescence resonance energy transfer study
46. Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions
47. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function
48. The evaluation of complex-dependent alterations in human factor VIIa
49. Importance of substrate composition, pH and other variables on tissue factor enhancement of factor VIIa activity
50. Serine proteases: Structure and mechanism of catalysis
51. Effect of soluble tissue factor on the kinetic mechanism of factor VIIa: Enhancement of p-guanidinobenzoate substrate hydrolysis
52. An ordered addition, essential activation model of the tissue factor pathway of coagulation: Evidence for a conformational cage
53. 2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation Factor X by activated Factor VII
54. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: Effects of calcium, phospholipids, and tissue factor
55. Substrate recognition by tissue factor-factor VIIa - Evidence for interaction of residues Lys165 and Lys166 of tissue factor with the 4-carboxyglutamate-rich domain of factor X
56. Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII
57. Tissue-factor coagulant activity of cultured human endothelial and smooth muscle cells and fibroblasts
58. Functional tissue factor is entirely cell surface expressed on LPS stimulated human blood monocytes and a constitutively tissue factor producing neoplastic cell line
59. Expression of tissue factor procoagulant activity: Regulation by cytosolic calcium
60. Transmembrane phospholipid distribution in blood cells: Control mechanisms and pathophysiological significance
61. Ligand-induced protease receptor translocation into caveolae: A mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway
62. Association of smooth muscle cell tissue factor with caveolae
63. Mechanism of tissue factor activation on HL-60 cells
64. Functional properties of factor VIIa/tissue factor formed with purified tissue factor and with tissue factor expressed on cultured endothelial cells
65. Extrinsic activation of human coagulation factors IX and X on the endothelial surface
66. Factor VIIa/tissue factor-catalyzed activation of factors IX and X on a cell surface and in suspension: A kinetic study
67. Autoactivation of human recombinant coagulation factor VII
68. Deletion of the membrane anchoring region of tissue factor abolishes autoactivation of factor VII but not cofactor function. Analysis of a mutant with a selective deficiency in activity
69. The biochemical basis for the apparent defect of soluble mutant tissue factor in enhancing the proteolytic activities of factor VIIa
70. Sphingosine-containing phospholipid vesicles support human factor VII autoactivation in the absence of tissue factor
71. Factor VIIa/tissue factor generates a form of factor V with unchanged specific activity, resistance to activation by thrombin, and increased sensitivity to activated protein C
72. Proteolysis of blood coagulation factor VIII by the factor VIIa-tissue factor complex: Generation of an inactive factor VIII cofactor
73. Tissue factor pathway inhibitor
74. Tissue factor pathway inhibitor and the current concept of blood coagulation
75. Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein
76. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor
77. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor
78. Regulation of factor VIIa in plasma: Evidence that antithrombin III is the sole plasma proteinase inhibitor of human factor VIIa
79. Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein
80. Kunitz domain inhibitors of tissue factor-factor VIIa. II. Potent and specific inhibitors by competitive phage selection
81. Characterisation of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties
82. Potent bifunctional anticoagulants: Kunitz domain tissue factor fusion proteins
83. Anticoagulant repertoire of the hookworm Ancylostoma caninum
84. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody
85. Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis
86. Tissue factor contributes to microvascular defects after focal cerebral ischemia
87. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries
88. Antithrombotic and anti-lesion benefits without hemorrhagic risks by inhibiting tissue factor pathway
89. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function
90. Therapeutic inhibition of thrombin activities, receptors, and production
91. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock
92. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis
93. Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: A comparison between tissue factor pathway inhibitor and inactive factor VIIa
94. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model
95. Role of tissue factor and factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon
96. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli
97. Active site-blocked activated factor VII as an effective antithrombotic agents: Mechanism of action
98. A comparison of methods for the measurement of activated factor VII
99. Coupled amidolytic assay for factor VII: Its use with a clotting assay to determine the activity state of factor VII
100. The estimation of activated human blood coagulation factor VII
101. Genetic determinants of plasma factor VII activity in the Japanese
102. Factor VII assays, plasma triglyceride levels, and cardiovascular disease risk
103. Fibrinogen and factor VII as risk factors in vascular disease
104. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: An international study
105. A novel specific immunoassay for plasma two-chain factor VIIa: Investigation of FVIIa levels in normal individuals and in patients with acute coronary syndromes
106. Two-chain factor VIIa generated in the pericardium during surgery with cardiopulmonary bypass - Relationship to increased thrombin generation and heparin concentration
107. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park heart study
108. Coagulation factors and the progress of coronary heart disease
109. Factor VII activity and ischaemic heart disease: Fatal and non-fatal events
110. Fibrinogen and factor VII in the prediction of coronary risk: Results from the PROCAM study in healthy men
111. Plasma factor VIIa: Measurement and potential clinical significance
112. Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction
113. 2+ signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor
114. 2+ oscillations in Madin-Darby canine kidney cells only when proteolytically active
115. Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor
116. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression
117. Coagulation of factors VIIa and Xa induce cell signaling leading to upregulation of the egr-1 gene
118. Factor VIIa/tissue factor-induced signaling via activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac
119. Sol Sherry lecture in thrombosis: How thrombin 'talks' to cells: Molecular mechanisms and roles in vivo
120. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa
121. Exclusion of known protease activated receptors in factor VIIa-induced signal transduction
122. Binding of factor VIIa to tissue factor induces alterations in gene expression in human fibroblast cells: Upregulation of poly(A) polymerase
123. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer
124. A new paradigm for blood coagulation research
125. Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extra-cellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa x tissue factor-induced signal transduction
126. Targeted disruption of the murine tissue factor gene results in embryonic lethality
127. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation
128. Role of tissue factor in embryonic blood vessel development
129. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system
130. Effect of tissue factor deficiency on mouse and tumor development
131. Diverse functions of protease receptor tissue factor in inflammation and metastasis
132. Binding of factor VIIa to tissue factor on human fibroblasts leads to activation of phospholipase C and enhanced PDGF-BB-stimulated chemotaxis
133. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages
134. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII
135. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa
136. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280
137. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor
138. Role of tissue factor in adhesion of mononuclear phagocytes to and trafficking through endothelium in vitro
139. RASMOL: Biomolecular graphics for all